A Pilot Study of Metformin to Reduce Cerebrovascular Dysfunction in Participants With HIV and Metabolic Syndrome.
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Metabolic syndrome is a constellation of risk factors for cardiovascular disease and type 2
diabetes mellitus which frequently occur together. Data is emerging suggesting metabolic
syndrome causes brain disease by contributing to blood vessel damage and inflammation. People
living with HIV (PLWH) are at high risk and the investigators will perform a pilot study of
the well-known type 2 diabetes drug metformin to treat this blood vessel damage and
inflammation in PLWH.
Phase:
Phase 2
Details
Lead Sponsor:
University of Stellenbosch
Collaborators:
Fogarty International Center of the National Institute of Health University of Rochester